摘要 |
Compounds of Formula (Ia), wherein R is a C<SUB>6</SUB>-C<SUB>12</SUB> substituted or unsubstituted aryl, a C<SUB>6</SUB>-C<SUB>12</SUB> substituted or unsubstituted heteroaryl, a C<SUB>1</SUB>-C<SUB>6</SUB> substituted or unsubstituted alkyl or -NR'R', Q is C(O), O, NR', S, S(O)<SUB>2</SUB>, C(O)<SUB>2</SUB> (CH2)p Y is C(O), O, NR', S, S(O)<SUB>2</SUB>, C(O)<SUB>2</SUB> (CH2)p Z is H or C<SUB>1</SUB>-C<SUB>4</SUB> alkyl, R' is H, C(O), S(O)<SUB>2</SUB>, C(O)<SUB>2</SUB>, a C<SUB>6</SUB>-C<SUB>12</SUB> substituted or unsubstituted aryl, a C<SUB>6</SUB>-C<SUB>12</SUB> substituted or unsubstituted heteroaryl or a C<SUB>1</SUB>-C<SUB>6</SUB> substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C<SUB>6</SUB>-C<SUB>12</SUB> heteroaryl, -NR'R' or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage. |
申请人 |
MOLECULAR INSIGHT PHARMACEUTICALS, INC.;BABICH, JOHN, W.;ZIMMERMAN, CRAIG, N.;MARESCA, KEVIN, P. |
发明人 |
BABICH, JOHN, W.;ZIMMERMAN, CRAIG, N.;MARESCA, KEVIN, P. |